D-0309-2025 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0309-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 11, 2025 and is designated Class II. Reason for recall: CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit. The recall status is ongoing. Affected quantity: 8160 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 9, 2025
Initiation Date
Mar 11, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8160 bottles

Product description

chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01

Reason for recall

CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.

Distribution pattern

Nationwide in the USA and PR

Code information

Lot#s: 17232222 and 17232237, Exp 10/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0309-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0309-2025. Report a data issue: hello@regdatalab.com.